European Commission expands Opdivo approval for lung and kidney cancer
The drug is already approved in Europe for use in previously treated patients with metastatic squamous NSCLC. Opdivo’s indication has now been expanded to include non-squamous NSCLC, which
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.